Skip to main content

Table 2 Relationship of SMC1A expression and clinicopathological parameters in colorectal cancer patients (n = 427)

From: Role of SMC1A overexpression as a predictor of poor prognosis in late stage colorectal cancer

Characteristic N SMC1A immunostaining Pa
- + ++ +++
Gender (n)       0.067
Male 240 21 (8.8%) 128 (53.3%) 80 (33.3%) 11 (4.6%)  
Female 186 20 (10.8%) 79 (42.5%) 82 (44.1%) 5 (2.7%)  
Age (years)       0.193
≤60 227 27 (11.9%) 112 (49.3%) 82 (36.1%) 6 (2.6%)  
>60 199 14 (7.0%) 95 (47.7%) 80 (40.2%) 10 (5.0%)  
Position       <0.0001
Colon cancer 209 6 (2.9%) 99 (47.4%) 93 (44.5%) 11 (5.3%)  
Rectal cancer 217 35 (16.1%) 108 (49.8%) 69 (31.8%) 5 (2.3%)  
Invasion depth       0.388
T1-T2 79 11 (13.9%) 34 (43.0%) 32 (40.5%) 2 (2.5%)  
T3-T4 347 30 (8.6%) 173 (49.9%) 130 (37.5%) 14 (4.0%)  
Lymph node metastasis       0.001
N0 229 10 (4.4%) 107 (46.7%) 103 (45.0%) 9 (3.9%)  
N1 131 19 (14.5%) 65 (49.6%) 41 (31.3%) 6 (4.6%)  
N2 66 12 (18.2%) 35 (53.0%) 18 (27.3%) 1 (1.5%)  
Distant metastasis       0.022
M0 372 40 (10.8%) 186 (50.0%) 133 (35.8%) 13 (3.5%)  
M1 54 1 (1.9%) 21 (38.9%) 29 (53.7%) 3 (5.6%)  
TNM       <0.0001
I 53 7 (13.2%) 22 (41.5%) 23 (43.4%) 1 (1.9%)  
II 159 3 (1.9%) 77 (48.4%) 71 (44.7%) 8 (5.0%)  
III 160 30 (18.8%) 87 (54.4%) 39 (24.4%) 4 (2.5%)  
IV 54 1 (1.9%) 21 (38.9%) 29 (53.7%) 3 (5.6%)  
Tumor differentiation       0.161
Well 13 1 (7.7%) 7 (53.8%) 5 (38.5%) 0 (0.0%)  
Moderately 358 30 (8.4%) 170 (47.5%) 143 (39.9%) 15 (4.2%)  
Poorly 55 10 (18.2) 30 (54.5%) 14 (25.5%) 1 (1.8%)  
Serum CEA       0.190
≤5 ng/mL 280 21 (7.5%) 137 (48.9%) 112 (40.0%) 10 (3.6%)  
>5 ng/mL 146 20 (13.7%) 70 (47.9%) 50 (34.2%) 6 (4.1%)  
Serum CA199       0.776
≤37 U/ml 358 31 (8.7%) 176 (49.2%) 138 (38.5%) 13 (3.6%)  
>37 U/ml 65 8 (12.3%) 31 (47.7%) 23 (35.4%) 3 (4.6%)  
Recurrence       0.536
No 338 34 (10.1%) 161 (47.6%) 132 (39.1%) 11 (3.3%)  
Yes 88 7 (8.0%) 46 (52.3%) 30 (34.1%) 5 (5.7%)  
  1. ausing Pearson Chi-Square test. 1 case is missing (0.2%).